NBTX vs PRQR
Nanobiotix S.a. and ProQR Therapeutics N.v., side by side — 5 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NBTX | PRQR |
|---|---|---|
| Revenue | €32.6M | €15.9M |
| Net income | €-24.0M | €-42.2M |
| Gross margin | · | · |
| Net margin | −73.5% | −265.2% |
| Return on equity | · | −61.2% |
| Diluted EPS | −€0.50 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-34.0M | €-53.8M |
| Equity | · | €49.4M |
| Net debt / equity | · | −1.77× |
| Current ratio | 1.09× | 3.09× |
| Revenue CAGR 5y | 67.0% | · |
| Profit CAGR 5y | · | · |
NBTX bills 2.0× the revenue of PRQR, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
Revenue by year
5 years side by side
| Fiscal year | NBTX | PRQR |
|---|---|---|
| FY2025 | €32.6M | €15.9M |
| FY2024 | €-7.2M | €18.9M |
| FY2023 | €36.2M | €6.5M |
| FY2022 | €4.8M | €3.6M |
| FY2021 | €2.6M | €1.3M |
Net income by year
Bottom line
| Fiscal year | NBTX | PRQR |
|---|---|---|
| FY2025 | €-24.0M | €-42.2M |
| FY2024 | €-68.1M | €-27.8M |
| FY2023 | €-39.7M | €-28.1M |
| FY2022 | €-57.0M | €-64.4M |
| FY2021 | €-47.1M | €-60.7M |
Revenue gap over time
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€16,687,000 | NBTX |
| FY2024 | −€26,096,000 | PRQR |
| FY2023 | +€29,693,000 | NBTX |
| FY2022 | +€1,182,000 | NBTX |
| FY2021 | +€1,312,000 | NBTX |
The higher-revenue side has changed between NBTX and PRQR over this period. The gap has widened since the earliest year compared.
5 of 8 comparable fiscal years — a year missing data on either side is not counted.